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Abstract
The mechanistic target of rapamycin (mTOR) functions as a critical regulator of cellular growth 
and metabolism by forming multi-component, yet functionally distinct complexes mTORC1 and 
mTORC2. Although mTORC2 has been implicated in mTORC1 activation, little is known about 
how mTORC2 is regulated. Here we report that phosphorylation of Sin1 at T86 and T398 
suppresses mTORC2 kinase activity by dissociating Sin1 from mTORC2. Importantly, Sin1 
phosphorylation, triggered by S6K or Akt, in a cellular context-dependent manner, inhibits not 
only insulin/IGF-1-mediated, but also PDGF or EGF-induced Akt phosphorylation by mTORC2, 
demonstrating a negative regulation of mTORC2 independent of IRS-1 and Grb10. Lastly, a 
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cancer patient-derived Sin1-R81T mutation impairs Sin1 phosphorylation, leading to hyper-
mTORC2 activation via bypassing this negative regulation. Together, our work reveals a Sin1 
phosphorylation-dependent mTORC2 regulation, providing a potential molecular mechanism by 
which mutations in the mTORC1/S6K/Sin1 signaling axis might cause aberrant hyper-activation 
of mTORC2/Akt that facilitates tumorigenesis.
Introduction
mTOR is a highly conserved important regulator of cell growth and proliferation in a 
plethora of biological settings in all eukaryotes 1–8. As such, deregulated mTOR function 
leads to a variety of human diseases, ranging from cancer 5,9 to immune dysfunction 3 and 
diabetes 4,10. mTOR functions as a critical and essential catalytic core in at least two known 
functionally distinct complexes, mTORC1 and mTORC2 3,5. A unique subset of associated 
proteins defines each complex, such as Raptor 11 in mTORC1, or Rictor 12 and Sin1 13–15 in 
mTORC2. Biologically, mTORC2 mainly promotes cell proliferation and survival 2,16 
through phosphorylation of the AGC kinase family members Akt and SGK 6, in addition to 
its initially defined role in regulating cell skeletal organization 17. On the other hand, 
mTORC1 directly promotes mRNA translation and protein synthesis by phosphorylating 
S6K1 and 4EBP1 18, inhibits autophagy through phosphorylating ULK1 19 and indirectly 
enhances ribosome biogenesis via promoting nucleophosmin (NPM) oncogene 
translation 20. As most mTORC1 functions are high energy consuming, regulation of 
mTORC1 activity is tightly coupled to the energy status of the cell and regulated by 
nutrients, energy, stress and growth factors, thereby ensuring that cells stop growing under 
unfavorable conditions 1,8,21,22.
Compared to well-defined mechanisms of mTORC1 activation such as mTORC2/Akt-
mediated phosphorylation of TSC2 23,24 or PRAS40 25,26, the upstream signaling that 
governs mTORC2 activation is just beginning to be appreciated. To this end, mTORC2’s 
association with ribosome was recently found to be necessary for its activation 4. 
Furthermore, mTORC1/S6K-mediated phosphorylation of IRS-1 27,28 and Grb10 28,29 also 
constitutes negative feedback mechanisms to block mTORC2 activation by insulin/IGF-1. 
However, both IRS-1 and Grb10 function by suppressing insulin/IGF-1 signaling upstream 
of PI3K to affect both mTORC1 and mTORC2. Thus, it remains elusive whether mTORC1 
could directly regulate mTORC2/Akt without broadly suppressing the PI3K pathway and 
how mTORC1 suppresses mTORC2/Akt in stimulation conditions other than insulin/IGF-1.
Here we show that in response to a wide spectrum of stimuli including insulin, IGF-1, PDGF 
and EGF, phosphorylation of Sin1 dissociates Sin1 from mTORC2 to terminate mTORC2 
kinase activity, revealing a negative regulation of mTORC2 function independent of the 
previously identified negative feedback regulators IRS-1 and Grb10 in suppressing 
mTORC2.
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Results
S6K phosphorylates Sin1 on both T86 and T398 sites
In keeping with previous reports 27–30, an inverse correlation between mTORC1/S6K and 
mTORC2 activities was confirmed (Supplementary Fig. S1a–d). Intriguingly, the critical 
role of Grb10 29,30 and IRS-1 27,28 in regulation of mTORC2/Akt was found to be restricted 
to insulin/IGF-1, but not PDGF or EGF stimulation (Supplementary Fig. S1e–g). 
Consistently, inhibition of mTORC1/S6K signaling by a specific S6K1 inhibitor, S6K1-I 31 
or mTORC1 inhibitor, rapamycin 11,32,33 could still augment Akt activation in TSC2−/− 
MEFs depleted of endogenous IRS-1 and/or Grb10 (Supplementary Fig. S1h–m), 
advocating that mTORC1/S6K could exert its negative regulation of mTORC2/Akt 
following PDGF or EGF stimulation through uncharacterized negative feedback loop(s) 
other than IRS-1 and Grb10. As Rictor and Sin1 are the only two unique essential mTORC2 
components 13,34, we reasoned that the mTORC1/S6K-dependent regulation of mTORC2 
might occur through Rictor or Sin1. However, S6K-dependent phosphorylation of Rictor 
does not affect mTORC2 kinase activity 32,35,36, which prompted us to investigate whether 
Sin1 is the primary target to mediate the regulation of mTORC2 by mTORC1/S6K.
In line with previous reports 13,15, insulin, IGF-1, PDGF and EGF all could effectively 
induce Akt S473 phosphorylation in WT but not Sin1−/− MEFs (Supplementary Fig. S1n) or 
Sin1 depleted TSC2−/− cells (Supplementary Fig. S1o). This finding prompted us to further 
examine whether other than IRS-1 and Grb10, modifications of Sin1 may play a critical role 
in mTORC1-mediated feedback regulation of mTORC2. In support of this hypothesis, 
phosphorylation of Sin1 was significantly reduced upon inhibition of mTORC1 or S6K, and 
moderately decreased by the Akt inhibitor, AktVIII (Fig. 1a). Consistently, we detected in 
vivo Sin1 phosphorylation triggered by S6K1 and to a lesser extent, Akt1, but not other 
characterized AGC kinases (Fig. 1b and Supplementary Fig. S2a). Notably, S6K1 inhibition 
led to reduced Sin1 phosphorylation while overexpressing a WT-S6K1 (Fig. 1c), but not a 
kinase-dead-S6K1 mutant 37 (Supplementary Fig. S2b), augmented Sin1 phosphorylation. 
Consistently, depletion of TSC2, which resulted in elevated S6K activity, also led to 
increased Sin1 phosphorylation (Supplementary Fig. S2c). In support of Sin1 being a S6K 
substrate, we identified two canonical AGC family kinase-recognition motifs (RxRxxpS/
pT) 38 located at T86 and T398, respectively (Fig. 1d). Notably, mutation of both sites to 
alanines abolished S6K1-mediated Sin1 phosphorylation in cells (Fig. 1e) or in vitro (Fig. 
1f). Interestingly, mutation of either T86 or T398 to an alanine did not completely abolish 
the S6K-dependent phosphorylation of Sin1 (Fig. 1e), indicating that both T86 and T398 
might be potential S6K1 sites in vivo.
Importantly, phosphorylation of T86 and T398 were detected by mass spectrometry 
(Supplementary Fig. S2d–e). To gain further mechanistic insights into how Sin1 
phosphorylation may affect mTORC2 activation under physiological conditions, we 
developed phospho-specific antibodies against pT86-Sin1 or pT398-Sin1, respectively 
(Supplementary Fig. S2f–g). Using these antibodies we observed an increase in Sin1-pT86 
and Sin1-pT398 upon induction by insulin (Fig. 1g and Supplementary Fig. S2h), IGF-1, 
PDGF or EGF (Fig. 1h), whereas these phosphorylation events could be attenuated by 
Liu et al. Page 3
Nat Cell Biol. Author manuscript; available in PMC 2014 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
inactivating S6K1 either through depleting Raptor (Fig. 1h and Supplementary Fig. S2i), or 
by S6K1-I (Supplementary Fig. S2j). Notably, S6K1 knockdown only partially reduced Sin1 
phosphorylation (Supplementary Fig. S2i), suggesting that other S6K isoforms might 
phosphorylate Sin1. Nevertheless, recombinant S6K1 phosphorylated Sin1 in vitro 
(Supplementary Fig. S2k) and conversely, rapamycin could attenuate Sin1-pT86 mediated 
by WT-S6K1 but not a rapamycin-resistant form of S6K1 37 (Supplementary Fig. 2l), 
further supporting S6K1 as a physiological kinase for Sin1.
Both Akt and S6K may phosphorylate Sin1 in a context-dependent manner
Although depletion of endogenous Akt1 also led to a moderate decrease in Sin1 
phosphorylation, its effects were less compared to inhibiting S6K1 or mTORC1 in our 
experimental conditions (Supplementary Fig. S2m–n). Moreover, Akt might regulate Sin1 
phosphorylation indirectly through activating mTORC1/S6K 11,13. In support of this model, 
Sin1-T86 phosphorylation correlated positively with S6K1 activity (evidenced by pS6) but 
inversely with Akt phosphorylation (Supplementary Fig. S2o–p), indicating that Sin1 
phosphorylation by S6K1 might act as a physiological negative regulator of Akt 
phosphorylation in fibroblasts. However, this conclusion might be cellular context-
dependent as a recent study has suggested Akt as the Sin1-T86 phosphorylating kinase in 
adipocytes 39.
To gain further mechanistic insights into upstream kinases responsible for phosphorylating 
Sin1, we examined the possible role of S6K versus Akt in mediating Sin1 phosphorylation 
on T86 and T398 in 3T3-L1 cells 40. Consistent with Humphrey et al 39, Sin1-pT86 signals 
were largely blocked by Akt inhibition, but only moderately reduced by inhibiting mTORC1 
or S6K (Supplementary Fig. S2q), confirming Akt as the major Sin1-T86 phosphorylating 
kinase in 3T3-L1 cells. However, inhibitors targeting either Akt or S6K1 led to a dramatic 
reduction in Sin1-pT398, suggesting that both Akt and S6K are involved in phosphorylating 
Sin1-T398 in 3T3-L1 adipocytes. On the other hand, in epithelium-derived HeLa cells, in 
stark contrast to 3T3-L1, inhibition of mTORC1/S6K, rather than Akt, led to a more severe 
reduction in both Sin1-pT86 and Sin1-pT398 signals (Supplementary Fig S2r), indicating 
that in HeLa cells, S6K, but not Akt, is the major kinase responsible for Sin1-T86 and -T398 
phosphorylation. Collectively, these results implicate that physiological upstream kinase(s) 
responsible for Sin1-T86 or Sin1-T398 phosphorylation might be tissue-specific or cellular 
context-dependent. A similar tissue specific phosphorylation atlas of mouse proteins has 
been established 41. Hence, adipocytes versus epithelial cells might require tightly regulated 
and specialized, phosphorylation-dependent intracellular signaling, thereby utilizing distinct 
upstream signaling routes to regulate effector pathways such as mTORC2. As carcinomas 
primarily derive from epithelial cells 42,43, we chose to focus on understanding how 
regulation of mTORC2 by S6K-mediated Sin1 phosphorylation contributes to tumorigenesis 
in the epithelial cell settings.
Phosphorylation of Sin1 at both T86 and T398 dissociates Sin1 from the mTORC2 complex
As Sin1 is an essential component that governs mTORC2 integrity 13–15, we next examined 
whether Sin1 phosphorylation on T86 and T398 affects mTORC2 function. Strikingly, 
compared to WT-Sin1, the Sin1 phospho-mimetic mutant (T86E/T398E, Sin1-EE), failed to 
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interact with the essential mTORC2 components Rictor, mTOR or GβL (Fig. 2a and 
Supplementary Fig. S3a–c), indicating that the assembly of a functional mTORC2 complex 
was prevented by Sin1 phosphorylation. In supporting of this model, S6K1-mediated 
phosphorylation of Sin1-WT, but not the Sin1 phospho-deficient mutant (T86A/T398A, 
Sin1-AA), reduced Sin1 interaction with Rictor (Fig. 2b), mTOR (Fig. 2c) and GβL (Fig. 
2d). Notably, disruption of the Sin1/Rictor interaction required Sin1 phosphorylation on 
both T86 and T398 (Supplementary Fig. S3d,e). To further investigate the underlying 
molecular mechanism(s), we performed gel-filtration assays to examine mTORC2 complex 
assembly in cells, and observed that WT-Sin1, but not Sin1-EE, co-eluted with mTORC2 
components including Rictor, mTOR, and GβL (Fig. 2e). Furthermore, depletion of TSC2 
led to elevated mTORC1/S6K activity and shifted a significant portion of Sin1 to mTORC2-
free fractions (Supplementary Fig. S3f,g). Strikingly, the mTORC2-free Sin1 species were 
enriched with pT86-Sin1 (Supplementary Fig. S3f). Consistently, less Rictor was detected in 
association with Sin1 in TSC2−/− cells (Fig. 2f), whereas inhibiting S6K1 activity in 
TSC2−/− cells by S6K1-I partially restored Rictor interaction with Sin1 (Supplementary Fig. 
S3h,i), supporting a crucial role of S6K in regulating the Sin1-Rictor interaction.
To further understand the role of each Sin1 phosphorylation event in mediating mTORC2 
complex organization, we truncated Sin1 into four regions (Fig. 2g) and observed that Sin1 
mainly interacts with Rictor through its N-terminal region, with mTOR kinase domain via 
its PH domain, and with GβL through its N, RBD and PH domains (Fig. 2h). Interestingly, 
phosphorylation of Sin1 at T86 in the N-terminal region abolished Sin1-N interaction with 
Rictor (Fig. 2i), while phosphorylation on T398 in the PH domain reduced Sin1 interaction 
with the mTOR kinase domain (Fig. 2j), indicating the distinct role of each phosphorylation 
site in possibly mediating the organization of the mTORC2 complex, further supporting that 
phosphorylation of both T86 and T398 is required to functionally inactivate mTORC2.
More importantly, under physiological stimulation conditions such as EGF (Fig. 3a and 
Supplementary Fig. S4a) or insulin (Fig. 3b and Supplementary Fig. S4b) induction, we 
observed an inverse correlation between the induced Sin1 phosphorylation and a 
dissociation of Sin1 from Rictor or mTOR, which could be abolished by mutating either T86 
or T398 to alanine (Fig. 3c), or by rapamycin treatment (Supplementary Fig. S4c–f), 
demonstrating a physiological role of Sin1 phosphorylation in negatively regulating 
mTORC2 function. Notably, compared with Sin1-WT, impairing Sin1 phosphorylation by 
mutating either T86 or T398 (Fig. 3d), inhibiting S6K activity (Fig. 3e and Supplementary 
Fig. S4g), or depleting endogenous Raptor (Supplementary Fig. S4h,i), led to sustained Akt 
phosphorylation under EGF or insulin stimulation. Conversely, activating S6K by either 
depletion of endogenous TSC2 (Supplementary Fig. S4j) or genetic ablation of TSC2 
(Supplementary Fig. S4k), resulted in reduced Akt S473 phosphorylation. In keeping with 
previous reports 27,44, Akt phosphorylation in response to various stimuli was attenuated in 
TSC2−/− cells with elevated S6K activity (Supplementary Fig. S4l), confirming a negative 
role for S6K-mediated phosphorylation of Sin1 in Akt activation.
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Phosphorylation of Sin1 on both T86 and T398 suppresses mTORC2-mediated activation 
of Akt
Notably, Sin1 phosphorylation did not affect Sin1 stability (Supplementary Fig. S4m,n). 
However, phosphorylation of Sin1 specifically reduced its interaction with the mTORC2 
substrate, Akt1 (Fig. 4a–c) but not with another characterized mTORC2 substrate 
SGK1 45,46 (Fig. 4d–e), nor the other AGC kinase S6K1 (Fig. 4f–g), which might explain 
why Sin1 phosphorylation leads to impaired Akt activation.
To further verify the critical roles of Sin1 phosphorylation in regulating mTORC2 kinase 
activity, we performed in vitro kinase assays to show that unlike Sin1-WT or Sin1-AA, 
immunoprecipitated Sin1-EE failed to phosphorylate GST-Akt1 in vitro, presumably due to 
its deficiency in forming a functional mTORC2 complex (Fig. 5a–b). By coupling gel 
filtration with in vitro kinase assays, we demonstrated that only the gel-filtration fractions 
with molecular weights corresponding to the full mTORC2 complex retained the mTORC2 
kinase activity towards GST-Akt in vitro (Fig. 5c–d). Strikingly, consistent with previous 
studies 47–49, insulin stimulation led to an oscillated pattern of Akt activation with reduced 
Akt phosphorylation after prolonged treatment in various cell lines (Supplementary Fig. 
S5a–c), a phenotype observed in many signaling pathways 47,50. However, the underlying 
mechanism of the oscillation of Akt phosphorylation remains not fully understood. Notably, 
prolonged (45 minutes of) insulin treatment led to a severe reduction of mTORC2-mediated 
in vitro phosphorylation of Akt in part by inducing pT86-Sin1 (Fig. 5c–d) to disrupt the 
mTORC2 complex integrity. More importantly, rapamycin treatment effectively restored 
mTORC2 complex integrity and kinase activity under prolonged EGF stimulation (Fig. 5e), 
emphasizing that S6K negatively regulates mTORC2 activity in part through 
phosphorylating Sin1, serving as a molecular switch to shut down EGF or insulin-induced 
activation of mTORC2/Akt in a timely fashion (Supplementary Fig. S5d).
Given the critical role of the mTORC2/Akt signaling in cell survival and tumorigenesis, we 
next examined the biological significance of S6K-mediated Sin1 phosphorylation on 
mTORC2 function. Consistent with in vitro kinase assay results (Fig. 5a), Sin1-WT, but not 
Sin1-EE, rescued in vivo Akt-S473 phosphorylation in Sin1−/− MEFs (Fig. 6a,b and 
Supplementary Fig. S6a) 13,15. Furthermore, in echoing the in vitro kinase results (Fig. 6c), 
immuno-purified endogenous Akt1 from Sin1-EE-expressing Sin1−/− MEFs was deficient in 
phosphorylating the well-characterized Akt substrate, crosstide 51,52 in vitro (Fig. 6d). 
Consistently, compared with Sin1-WT expressing Sin1−/− cells, Sin1−/− cells expressing 
Sin1-EE exhibited reduced levels of phospho-FOXOs (Fig. 6a) 53, thereby more sensitive to 
cell death 54,55 induced by etoposide (Fig. 6e,f and Supplementary Fig. S6b–e) or cisplatin 
(Fig. 6g). Similar apoptotic sensitization was observed after introducing Sin1-EE, in 
comparison to Sin1-WT, into Sin1-depleted OVCAR5 cells (Supplementary Fig. S6f–i, 
supporting a physiological role of Sin1 phosphorylation in regulating cellular survival in 
part through the Akt/FOXO signaling pathway 56,57.
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The ovarian cancer patient-derived Sin1-R81T mutation displayed elevated oncogenic 
activity in part by bypassing Sin1 phosphorylation-mediated suppression of mTORC2/Akt 
signaling
Interestingly, two natural Sin1 mutations (R81T and S84L) were recently identified in 
ovarian cancer patients 58 and skin cancer patients, respectively (Fig. 7a) from two 
publically available cancer genome databases: the Cosmic database (http://
cancer.sanger.ac.uk/cancergenome/projects/cosmic/) 59 and the CBio database (http://
www.cbioportal.org/public-portal/) 60. Notably, these mutations appear to disrupt the 
canonical S6K phosphorylation motif (Fig. 7a), and indeed we observed a significant 
reduction in pT86 in both Sin1-R81T (Fig. 7b) and S84L (Supplementary Fig. S7a–b) 
mutants, suggesting that they functionally mimicked Sin1-T86A. More importantly, a 
synthesized pT86-containing peptide could be efficiently recognized by the Sin1-pT86 
antibody regardless of Sin1-R81T mutation status (Fig. 7c), excluding a secondary antibody 
effect. As the R81T mutant impairs the stringent AGC substrate motif, we focused on 
studying the pathophysiological effects of this mutant in cells.
We found that Sin1-pT86 signal was nearly abolished in the Sin1-R81T mutant in response 
to a wide spectrum of stimuli, including insulin, IGF-1, PDGF and EGF (Fig. 7d). Unlike 
WT-Sin1 (Fig. 3b–c), R81T-Sin1 demonstrated a relatively sustained interaction with 
mTORC2 components (Fig. 7e and Supplementary Fig. S7c,d), resulting in prolonged 
mTORC2 kinase activity towards phosphorylating Akt in vitro (Fig. 5d). In keeping with 
these results, in response to various external stimuli including EGF (Fig. 7f and 
Supplementary Fig. S7e), insulin (Fig. 7g) and PDGF (Supplementary Fig. S7f), there is a 
more sustained Akt activation in Sin1-R81T compared with Sin1-WT expressing OVCAR5 
cells. These results support a model that the R81T mutation may enhance tumorigenesis in 
part through augmenting Akt activation (Supplementary Fig. S7g).
Biologically, expression of Sin1-R81T in either Sin1−/− MEFs or shSin1-OVCAR5 cells led 
to elevated phosphorylation of Akt and the Akt substrate FOXOs (Supplementary Fig. 
S8a,b), which subsequently conferred resistance to etoposide (Fig. 8a and Supplementary 
Fig. S8c–g) or cisplatin (Fig. 8b,c). Moreover, re-introduction of R81T, but not WT-Sin1, 
significantly promoted the anchorage-independent growth of Sin1-depleted OVCAR5 cells, 
arguing that R81T is a gain-of-function oncogenic mutation that favors cellular 
transformation (Fig. 8d). This finding was echoed by the significantly enhanced in vivo 
tumor formation ability of R81T expressing OVCAR5 cells in a mouse xenograft model, 
(Fig. 8e–g and Supplementary Fig. 8h). Although further investigation is required, these 
results provide an important clinical relevance for the oncogenic role of Sin1-R81T mutant, 
in part by bypassing the mTORC1-S6K-mediated negative feedback regulation on 
mTORC2/Akt activation. Interestingly, we observed that Sin1-R81T-expressing OVCAR5 
cells are more resistant to the Akt inhibitor, AktVIII (Supplementary Fig. S8i–k), indicating 
that cancer patients bearing the Sin1-R81T mutation might poorly respond to Akt or mTOR 
inhibitor treatments.
Given that abnormal mTORC2/Akt activities are associated with numerous human 
diseases 3,6,7, impaired Sin1 phosphorylation (such as caused by the R81T mutation) might 
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contribute to deregulated mTORC2/Akt activity in many types of tissues and diseases. In 
this regard, we found that rapamycin treatment attenuated Sin1 T86 phosphorylation in 
splenic B cells freshly isolated from mice, leading to elevated Akt phosphorylation in vivo 
(Supplementary Fig. S8l–o). Similar results were also observed from rapamycin-treated 
mouse livers (Fig. 8h). Consistently, an inverse correlation between pT86-Sin1 and pS473-
Akt was observed in a panel of T-ALL cell lines as well as in ovarian caner patient samples 
(Fig. 8i and Supplementary Fig. S8p–r), emphasizing the possible pathological importance 
of the identified negative feedback mechanism in human cancer settings. However, further 
studies with larger sample sizes are warranted to determine a significant inverse correlation 
between pT86-Sin1 and pS473-Akt.
Discussion
Recent studies have begun to reveal a complicated cross-communication between the two 
mTOR-containing complexes mTORC1 and mTORC2, while the exact molecular 
mechanism(s) remain largely elusive. Here we define an independent negative feedback 
regulation through which S6K or Akt directly phosphorylates Sin1 to repress mTORC2 
activation in epithelial cells or adipocytes, respectively, thereby providing further molecular 
insights into a direct and efficient strategy to timely suppress the mTORC2/Akt signaling in 
a possible tissue and cellular context dependent manner. Nonetheless, phosphorylation of 
both T86 and T398 of Sin1 is required for the complete inactivation of mTORC2 kinase 
activity in part by dissociating Sin1 from other mTORC2 components.
As illustrated in Supplementary Fig. S8s, mTORC1 could be regulated indirectly by 
mTORC2 in response to extra cellular growth factors, or controlled by multiple in vivo 
signal fluxes, such as amino acids, nutrients and stresses. As frequently observed in many 
signaling pathways like those initiated by Ras or PI3K 61, the mTORC2-mediated growth 
factor signal is only activated transiently followed by a quench of the signaling through 
multiple negative feedback regulations to ensure that their activations are presented only in a 
“pulse” manner 62. Most significantly, an ovarian cancer patient-derived R81T mutation of 
Sin1 could bypass the identified Sin1 phosphorylation-mediated negative regulation of 
mTORC2 due to the lack of Sin1 phosphorylation motif, providing a molecular mechanism 
for the elevated mTORC2/Akt activation that could potentially promote tumorigenesis in the 
ovarian cancer settings. In summary, our work identified a negative regulation mechanism 
mediated largely by Sin1 phosphorylation on both T86 and T398 to specifically suppress 
mTORC2 integrity and kinase activity towards Akt-S473 phosphorylation. Moreover, we 
demonstrated that deregulation of this negative regulation in pathological conditions may 
contribute to accelerated tumor formation.
Methods
Methods and any associated references are available in the online version of the paper.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. S6K phosphorylates Sin1 on both T86 and T398 sites
a. Immunoblot (IB) analysis of whole cell lysates (WCL) and Flag-immunoprecipitates (IP) 
derived from Flag-Sin1-transfected HeLa cells that were serum-starved for 24 hours and 
then collected after serum stimulation for 30 minutes. Where indicated, the kinase inhibitors 
(AktVIII: 10 μM, PP242: 1 μM, Rapamycin: 20 nM, S6K1-I: 10 μM) were added together 
with insulin (100 nM). DMSO was used as a negative control.
b. IB analysis of WCL and IP derived from 293T cells transfected with Flag-Sin1 and the 
indicated HA-tagged constitutive active AGC family kinases.
c. IB analysis of WCL and IP derived from 293T cells transfected with Flag-Sin1 and HA-
S6K1 (or empty vector as a negative control). Where indicated, the S6K inhibitor was 
added.
d. Schematic illustration of the two evolutionarily conserved putative S6K phosphorylation 
sites, T86 and T398 within Sin1.
e. IB analysis of WCL and IP derived from 293T cells transfected with constitutive active 
form of S6K (HA-S6K-R3A) and the indicated Flag-Sin1 constructs.
f. In vitro kinase assays depicting major S6K phosphorylation sites in Sin1. Please note that 
the GST-Rictor fusion protein used here is not the full-length protein but rather the truncated 
version that contains the S6K phosphorylation site T1135 (GST-Rictor-C-tail [aa1390–
1708]).
g. IB analysis of WCL and Flag-IP derived from HeLa cells transfected with the indicated 
Flag-Sin1 constructs. Where indicated, cells were serum starved for 12 hours and stimulated 
by 100 nM insulin for 30 minutes before harvesting.
h. IB analysis of WCL and Flag-IP derived from HeLa cells depleted of Raptor transfected 
with Flag-Sin1 (shGFP as a negative control). Where indicated, cells were serum starved for 
12 hours and stimulated by the indicated stimuli before harvesting.
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Figure 2. S6K-dependent phosphorylation of Sin1 dissociates Sin1 from the mTORC2 complex
a. Immunoblot (IB) analysis of whole cell lysates (WCL) and Flag immunoprecipitates (IP) 
derived from 293T cells transfected with the indicated Flag-Sin1 constructs (EV: empty 
vector control; WT: Sin1-WT; AA: Sin1-T86A/T398A; EE: Sin1-T86E/T398E).
b–d. GST pull down assays to demonstrate that S6K phosphorylation of GST-Sin1-WT-FL 
(full-length) but not GST-Sin1-T86A/T398A led to impaired interaction with Rictor (b), 
mTOR-kinase domain (KD) (c) or GβL (d). As indicated, GST-Sin1 proteins were 
phosphorylated by active recombinant S6K in vitro for 1 hour before using as a bait to pull 
down HA-Rictor (b), mTOR-kinase domain (KD) (c) or GβL (d) expressed in 293T cells.
e. Gel filtration experiments to illustrate that comparing with WT-Sin1, Sin1-EE lost 
interaction with the functional mTORC2 complex components in vivo. IB analysis of the 
indicated fractionations derived from the gel filtration experiment with HeLa cells co-
transfected with HA-Sin1-WT and Flag-Sin1-EE constructs. Prior to running cell lysates, the 
molecular weight resolution of the column was first estimated by running native molecular 
weight markers (Thyroglobulin ~669KD, Ferritin ~440KD, Aldolase ~158KD, Conalbumin 
~75KD and Ovalbumin ~44KD) to determine their retention times on coomassie-stained 
SDS-PAGE protein gels.
f. Deletion of endogenous TSC2, which led to increased S6K kinase activity, resulted in a 
reduction of Rictor association with Sin1. IB analysis of WCL and anti-Sin1-IP derived 
from TSC2+/+ or TSC2−/− MEFs.
g. Schematic representation of the indicated domains of Sin1 as well as the locations of the 
two Sin1 phosphorylation sites: T86 is in the N-terminal domain while T398 is located in the 
PH domain.
h. GST pull down assays to depict the Sin1 domains that interact with Rictor, mTOR-KD or 
GβL, respectively (* indicates the sizes of GST-Sin1 proteins).
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I–j. GST pull down assays to demonstrate that Sin1 T86E or T398E mutation led to reduced 
interaction with Rictor (i) or mTOR-KD (j), respectively.
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Figure 3. Sin1 phosphorylation induced by various stimuli impairs mTORC2 integrity
a. Immunoblot (IB) analysis of whole cell lysates (WCL) and endogenous Sin1 
immunoprecipitates (IP) derived from Sin1-WT MEFs that were serum-starved for 24 hours 
and then collected after EGF (100 ng/ml) stimulation for the indicated time periods.
b. IB analysis of WCL and Flag-IP derived from Flag-Sin1-transfected HeLa cells that were 
serum-starved for 24 hours and then collected after insulin stimulation for the indicated time 
periods.
c. Either Sin1-T86A or T398A mutation impaired the dynamic interaction between Sin1 and 
other essential mTORC2 components. IB analysis of WCL and Flag-IP derived from HeLa 
cells transfected with the indicated Flag-Sin1 constructs that were serum starved for 12 
hours and then treated with the EGF (100 ng/ml) for the indicated time periods before 
harvesting for IB analysis.
d. Either Sin1-T86A or T398A mutation led to sustained Akt activation upon EGF 
stimulation. IB analysis of WCL derived from HeLa cells transfected with the indicated 
Flag-Sin1 constructs that were serum starved for 12 hours and then treated with the EGF 
(100 ng/ml) for the indicated time periods before harvesting for IB analysis.
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e. Rapamycin or S6K1-I treatment led to a relatively sustained Akt-pS473 upon insulin 
stimulation. IB analysis of WCL derived from HeLa cells serum starved for 12 hours and 
stimulated with 100 ng/ml insulin before harvesting at the indicated time points. Where 
indicated, 20 nM rapamycin or 10 μM S6K1-I was added.
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Figure 4. Sin1 phosphomimetic mutation is deficient in interacting with the mTORC2 substrate 
Akt1, but not SGK1
a–b. Immunoblot (IB) analysis of whole cell lysates (WCL) and HA (a) or Flag (b) 
immunoprecipitates (IP) derived from 293T cells that were transfected with the indicated 
Flag-Sin1 constructs with HA-Akt1.
c. Sin1-T86E or Sin1-T398E disrupts Sin1-N-terminus or Sin1-PH domain interaction with 
Akt1. Indicated GST-Sin1 proteins were used as a bait to pull down HA-Akt1 expressed in 
293T cells.
d–e. IB analysis of WCL and HA-IP derived from 293T cells that were transfected with the 
indicated Flag-Sin1 constructs with HA-SGK-Δ60.
f–g. IB analysis of WCL and HA-IP or Flag-IP derived from 293T cells that were 
transfected with the indicated Flag-Sin1 constructs with HA-S6K1.
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Figure 5. Sin1 phosphorylation suppresses mTORC2 kinase activity towards phosphorylating 
Akt in vitro
a–b. 293T cells were transfected with the indicated Flag-tagged Sin1 constructs. 36 hours 
post-transfection, whole cell lysates (WCL) were collected and the mTORC2 complex was 
purified by Flag-immunoprecipitation (IP). The Flag-IPs were incubated in vitro with 
purified GST-Akt1 in the presence of ATP and the kinase reaction buffer. Thirty minutes 
later, the reaction was stopped by the addition of the loading buffer. Akt1 phosphorylation 
status was examined by immunoblot (IB) analysis.
c–d. Prolonged insulin treatment (45 min) induces Sin1 phosphorylation, leading to 
dissociation of mTORC2 complex and abolished Akt activation. Flag-Sin1-WT or R81T 
mutant was transfected into HeLa cells and 48 hours later the transfected cells were 
harvested upon insulin (100 nM) stimulation for 45 min after 12 hours of serum starvation in 
CHAPS buffer. The whole cell lysates were filtered and run through FPLC superdex 200 
column. 500 μL elute was collected for each fraction and 1/20 volume of each fraction was 
incubated with 2 μg GST-Akt-tail (aa 408–480) at 30°C for 30 min. Afterwards, the 
resulting samples were resolved on SDS-PAGE and subjected to IB analysis.
e–f. Rapamycin treatment restored Sin1 phosphorylation resulted from EGF treatment, 
leading to reassembly of mTORC2 complex and Akt activation. Flag-Sin1-WT was 
transfected into TSC2-depleted HeLa cells and 24 hours later, the transfected cells were 
treated with 20 nM rapamycin for another 12 hours prior to EGF stimulation (100 nM) 
before harvested and analyzed as in (c–d).
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Figure 6. Sin1 phosphorylation attenuates mTORC2 kinase activity towards phosphorylating 
Akt in vivo
a. Sin1−/− MEFs were transfected with the indicated Flag-Sin1 constructs. 30 hours post-
transfection, the resulting cells were serum-starved for 24 hours and then collected after 
stimulation with insulin for 30 minutes for immunoblot (IB) analysis.
b. Reconstitution of Sin1−/− MEFs with WT-, but not EE-Sin1, could restore Akt-Ser473 
phosphorylation under various stimulation conditions. Sin1−/− MEFs were transfected with 
the indicated Flag-Sin1 constructs and serum-starved for 24 hours before harvesting after 
treatment with indicated stimuli for IB analysis.
c. The indicated Flag-Sin1 constructs were transfected into Sin1−/− MEFs and Flag 
immunoprecipitation (IP) was recovered as the kinase source to phosphorylate GST-Akt1-
tail (aa 408–480) in vitro.
d. The indicated Flag-Sin1 constructs were transfected into Sin1−/− MEFs and endogenous 
Akt IP was performed as the kinase source to phosphorylate crosstide in vitro. Data was 
shown as mean ± SD for n= 3 independent experiments.
e–g. Sin1−/− MEFs were transfected with the indicated Flag-Sin1 constructs (with empty 
vector as a negative control). 24 hours post-transfection, the resulting cells were cultured in 
10% FBS-containing medium with the indicated concentrations of etoposide (e) or cisplatin 
(f) for 48 hours before performing the cell viability assays (e,f) or IB analysis (g). Data was 
shown as mean ± SD from n=3 independent experiments. * indicates p < 0.05 (Student’s t-
test).
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Figure 7. The pathological Sin1-R81T mutation led to attenuated Sin1-T86 phosphorylation and 
sustained Akt phosphorylation upon physiological stimulations
a. Schematic illustrations of the ovarian cancer patient-derived Sin1-R81T mutation and the 
skin cancer patient-derived S84L mutation.
b. Immunoblot (IB) analysis of whole cell lysate (WCL) and Flag-immunoprecipitates (IP) 
derived from 293T cells transfected with the indicated Flag-Sin1 constructs and HA-S6K1.
c. Sin1-R81T does not interfere with the Sin1-pT86 antibody to recognize Sin1-pT86. 
Indicated Sin1 synthetic peptides were dotted on nitrocellulose membrane for IB analysis.
d. HeLa cells were transfected with the indicated Flag-Sin1 constructs and serum-starved for 
24 hours and then collected after stimulation with the indicated stimuli for 30 minutes for IB 
analysis and Flag-IP.
e. Sin1−/− MEFs were transfected with the indicated Flag-Sin1 constructs and serum-starved 
overnight followed by IB analysis upon 100 ng/ml EGF stimulation for the indicated time 
points.
f–g. Sin1 depleted OVCAR5 cells stably expressing Sin1-WT or -R81T were serum starved 
overnight followed by IB analysis after treatment with 100 ng/ml EGF (f) or 100 nM insulin 
(g) for the indicated time points.
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Figure 8. The pathological Sin1-R81T mutation displayed elevated oncogenic activity in part by 
bypassing Sin1 phosphorylation-mediated negative regulation of Akt-pS473
a–c. Sin1−/− MEFs were transfected with the indicated Flag-Sin1 constructs and were 
treated with the indicated concentrations of etoposide (a) or cisplatin (b,c) for 48 hours 
before performing the cell viability assays (a,b) or immunoblot (IB) analysis (c). Data was 
shown as mean ± SD from n=3 independent experiments. * indicates p < 0.05 (t-test).
d. Soft agar assays for Sin1-depleted OVCAR5 cells stably expressing EV, WT or R81T. 
Data was presented as mean ± SD from n=3 independent experiments.
e–f. Growth curves (e) and mass of the dissected tumors (f) from xenograft experiments with 
the indicated cells injected subcutaneously into n=10 mice for each cell line. The visible 
tumors were measured at the indicated days. Error bars, ±SEM and * indicates p < 0.05 (t-
test).
g. Representative images of the dissected tumors presented in Figure 8e,f.
h. Eight-week-old mice were fasted overnight and then refed for 6 hours following a 30 min 
pretreatment with vehicle or rapamycin (10 mg/kg). N=4 mice per condition. Livers were 
dissected and liver lysates were subjected to IB analysis.
i. Four representative images of IHC with indicated Sin1 and Akt phosphorylation status out 
of 58 ovarian patient samples under 400x magnification. Scale bar represents 100 μm.
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